Aridis Pharmaceuticals, Inc. (ARDS)
$1.86
Rating:
Recommendation:
-
| Symbol | ARDS |
|---|---|
| Price | $1.86 |
| Beta | 1.133 |
| Volume Avg. | 0.13M |
| Market Cap | 32.925M |
| Shares () | - |
| 52 Week Range | 0.88-4.34 |
| 1y Target Est | - |
| DCF Unlevered | ARDS DCF -> | |
|---|---|---|
| DCF Levered | ARDS LDCF -> | |
| ROE | 137.98% | Strong Buy |
| ROA | -75.55% | Strong Sell |
| Operating Margin | - | |
| Debt / Equity | -216.70% | Sell |
| P/E | - | |
| P/B | -1.61 | Sell |
Latest ARDS news
About
Download (Excel)Aridis Pharmaceuticals, Inc., a late-stage biopharmaceutical company, focuses on the discovery and development of targeted immunotherapy using fully human monoclonal antibodies (mAb) to treat life-threatening infections. Its lead product candidate is AR-301, a fully human mAb of immunoglobulin 1 (IgG1) that is in Phase III pivotal trials for the treatment of lung infections resulting from S. aureus alphatoxin. The company is also developing AR-320 is a fully human IgG1 monoclonal antibody targeting S. aureus alpha toxin to treat infections caused by methicillin-resistant Staphylococcus aureus and methicillin-susceptible S. aureus; AR-105, a fully human IgG1 mAb, which is in Phase II trials to target gram-negative bacteria P. aeruginosa; AR-101, a human IgM mAb, which is in Phase IIa clinical trials for the treatment of hospital-acquired pneumonia (HAP)and ventilator-associated pneumonia (VAP) caused by P. aeruginosa serotype O11; AR-401 that is in preclinical stage to treat infections caused by Acinetobacter baumannii; AR-201, a fully human IgG1 mAb preclinical program for respiratory syncytial virus; and AR-501, an anti-infective therapy, which is in Phase I/IIa clinical trial to manage chronic lung infections in cystic fibrosis patients. In addition, it is developing AR-712 and AR-701, a cocktail of two fully human immunoglobulin 1, or IgG1, mAbs, which is in Phase I/II clinical for the treatment of mild to moderate non-hospitalized COVID-19 patients. Aridis Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Los Gatos, California.